Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors (Yahoo Finance) - Aug 18, 2026 - "The development of HBM7004 further demonstrated the HBICE platform's versatility and plug-and-play advantages. In preclinical studies, HBM7004 demonstrated an intratumor B7H4-dependent T cell activation manner. In multiple animal models, HBM7004 showed strong anti-tumor efficacy, remarkable in vivo stability, and reduced systemic toxicity. Additionally, in preclinical models, HBM7004 exhibited a strong synergistic effect when combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, indicating an encouraging therapeutic window."
New trial • Preclinical • Solid Tumor
|